Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern within twelve months following the issuance date of these financial statements. Our future viability depends on the successful execution of our strategic plans, securing additional near-term financing, and achieving profitable operations.”View the 10-Q filed Oct 15, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Biomerica's proxy statement seeks stockholder votes at its December 11, 2026 annual meeting to elect five directors, ratify Haskell & White LLP for the fiscal year ending May 31, 2027, and amend the 2024 Stock Incentive Plan to add 150,000 shares.
Biomerica reported sales of $1,265,000 for the three months ended August 31, 2026, down $115,000 or 8%, amid substantial doubt about going concern. Medicare-related inFoods® IBS orders rose to 22 in September 2026, and a private placement generated approximately $2,231,000.
Biomerica Inc. reported that David Moatazedi will not stand for re-election at the December 11, 2026 Annual Meeting; his departure was not due to any dispute or disagreement with the company or Board.
Biomerica Inc. amended and restated Part III of its 2026 Annual Report and filed new certifications. Xiaoxuan (“Jenny”) Qu became Principal Financial Officer and Principal Accounting Officer effective August 27, 2026.
Biomerica Inc. established a $250,000,000 shelf registration for common stock, preferred stock, debt securities and warrants offered from time to time. Its common stock trades on Nasdaq Capital Market under “BMRA,” last reported at $2.60 per share on September 23, 2026.
Biomerica registered the proposed resale of up to 1,403,705 common shares by selling stockholders, comprising 1,393,705 shares issued in a private placement and 10,000 shares issued to Jeb B. Terry, Sr.; Biomerica will receive no proceeds.
